Cardiovascular Systems

Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardiovascular Systems, Inc. (CSI) is devoted to developing and commercializing innovative solutions for treating peripheral and coronary vascular disease. Their primary focus is helping physicians conquer even the most difficult disease states, including calcium, given the complications. Cardiovascular Systems develop solutions for the treatment of peripheral and coronary artery disease, to help physicians conquer calcium, one of the largest challenges when treating PAD and CAD.

This is a major achievement for Cardiovascular Systems (CSII) toward strengthening its portfolio for the treatment of CLI.

Cardiovascular Systems Sees Peripheral OAS Micro Crown Success

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?

Cardiovascular Systems (CSII) Up 6.2% Since Last Earnings Report: Can It Continue?

We are upbeat about the year-over-year uptick in both Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.

Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q1

Cardiovascular Systems, Inc's (CSII) CEO Scott Ward on Q1 2020 Results - Earnings Call Transcript

Why Is Cardiovascular Systems (CSII) Up 1.8% Since Last Earnings Report?

Cardiovascular Systems Inc (CSII) Files 10-K for the Fiscal Year Ended on June 30, 2019

This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).

Cardiovascular Systems Set to Present LIBERTY 360 Outcome

We are upbeat about the year-over-year uptick in Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.

Cardiovascular Systems (CSII) Earnings Match Estimates in Q4

Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q4 2019 Results - Earnings Call Transcript

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 0.00% and 3.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Cardiovascular Systems (CSII) Meets Q4 Earnings Estimates

Bank of America

Goldman Sachs

Magellan Health

Molina Healthcare

Repligen

Some analysts have started to price in "insurance cuts," which means they are expecting the Fed to cut rates right before a downturn in order to save the economy.

Wall Street Foresees a Fed Rate Cut: Winners & Losers

Aurora Cannabis

Haemonetics

Intuitive Surgical

QuidelOrtho Corp

Medical Products Industry Outlook: Growth Prospects Radiant

Cardiovascular Systems (CSII) gains on high investors' confidence, courtesy of consistent positive results.

Here's Why You Should Add Cardiovascular Systems (CSII) Stock

Cardiovascular Systems (CSII) Up 6.4% Since Last Earnings Report: Can It Continue?

Cardiovascular Systems (CSII) rides high on a year-over-year rise in both Coronary and peripheral device revenues.

Cardiovascular Systems (CSII) Q3 Earnings Top, View Tapered

Cardiovascular Systems' (CSII) CEO Scott Ward on Q3 2019 Results - Earnings Call Transcript

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 150.00% and 0.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Cardiovascular Systems (CSII) Q3 Earnings and Revenues Top Estimates

News for Cardiovascular Systems Stock (CSII)